Sugi Predict

Sugi Predict / Compounds / SCHEMBL1707168

SCHEMBL1707168

SCHEMBL1707168

COC(=O)c1ccc(OC2CCOCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HRH3 Q9Y5N1 1/20 0.53
▸ EPHX2 P34913 3/20 0.52
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ HPGD P15428 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ MGLL Q99685 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ FAAH O00519 1/20 0.50
▸ PARP10 Q53GL7 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ACACB O00763 1/20 0.47
▸ KAT2B Q92831 1/20 0.47
▸ BAZ2B Q9UIF8 1/20 0.47
▸ PDE4D Q08499 2/20 0.46
▸ PDE4A P27815 1/20 0.46
▸ PDE4B Q07343 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19869213 0.91 CA1 (0.49) MEN1KMT2AHRH3EPHX2CA1
SCHEMBL19870508 0.91 CA1 (0.49) MEN1KMT2AHRH3EPHX2CA1
SCHEMBL19870507 0.91 CA1 (0.49) MEN1KMT2AHRH3EPHX2CA1
SCHEMBL16147114 0.89 EPHX2 (0.61) MEN1KMT2AEPHX2CA1CA2
SCHEMBL8339652 0.85 PARP10 (0.60) EPHX2CA1CA2ALDH1A1FAAH
SCHEMBL12372144 0.84 PARP10 (0.51) HRH3ALDH1A1PARP10ACACBKAT2B
SCHEMBL15830297 0.84 PARP10 (0.58) MEN1KMT2AEPHX2CA1CA2
SCHEMBL13266896 0.84 EPHX2 (0.57) EPHX2CA1CA2FAAHPARP10
SCHEMBL7326433 0.84 PARP10 (0.58) MEN1KMT2AEPHX2CA1CA2
SCHEMBL1169295 0.84 EPHX2 (0.54) HRH3EPHX2CA1CA2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 — — US disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
US-20210308121-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2021-10-07 — — US disclosed
US-20210308121-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2021-10-07 — — US disclosed
US-10980794-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2021-04-20 — — US disclosed
US-10980794-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2021-04-20 — — US disclosed
US-20190343826-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2019-11-14 — — US disclosed
US-20100204242-A1 Piperazine Derivative Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2010-08-12 — — US disclosed
US-20100204242-A1 Piperazine Derivative Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2010-08-12 — — US disclosed
EP-2195307-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR Glaxo Group Limited (GB) 2010-06-16 — — EP disclosed
WO-2010023170-A1 Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof GLAXO GROUP LIMITED (GB) 2010-03-04 — — WO disclosed
WO-2010018231-A2 SALT OF, AND PROCESSES FOR THE PREPARATION OF, 1-ISOPROPYL-4-{[4-(TETRAHYDRO-2H-PYRAN- 4-YLOXY)PHENYL]CARBONYL}HEXAHYDRO-1H-1,4-DIAZEPINE GLAXO GROUP LIMITED (GB) 2010-02-18 — — WO disclosed
US-20090170869-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-07-02 — — US disclosed
US-20090170869-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-07-02 — — US disclosed
US-20090170869-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-07-02 — — US disclosed
WO-2009030716-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-03-12 — — WO disclosed
WO-2009030716-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210308121-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 MEN1 1329/4885KMT2A 58/4885HRH3 1460/4885
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 MEN1 3131/4885KMT2A 155/4885HRH3 1154/4885
US-20190343826-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 MEN1 1665/4885KMT2A 48/4885HRH3 629/4885
US-20090170869-A1 PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 MEN1 2486/4885KMT2A 74/4885HRH3 1/4885
US-20100204242-A1 Piperazine Derivative Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH1 MEN1 2486/4885KMT2A 74/4885HRH3 1/4885
US-10980794-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT6 MEN1 1329/4885KMT2A 58/4885HRH3 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.